• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRETINOIN Drug Record

  • Summary
  • Interactions
  • Claims
  • TRETINOIN chembl:CHEMBL38 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    RENOVA
    ALTRENO
    TRETINOIN
    ATRALIN
    TRETIN-X
    ACTICIN
    RETIN-A MICRO
    RETIN-A
    RETINOIC ACID
    RETIN-A-MICRO
    AVITA
    NSC-122758
    VESANOID
    TRETINOINE (FRENCH)
    TRETINOINUM
    AVITA®
    ALL-TRANS-TRETINOIN
    (ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOIC ACID
    VITAMIN A ACID
    ALL-TRANS-BETA-RETINOIC ACID
    (ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOATE
    3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENE-1-YL)-2,4,6,8-NONATETRAENOIC ACID (ECL)
    ALL-(E)-RETINOATE
    ALL TRANS-RETINOIC ACID
    3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOIC ACID
    TRETINOINE (FRENCH) (EINECS)
    STIEVA-A
    BETA-RETINOATE
    ACIDE RETINOIQUE (FRENCH) (DSL)
    3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOATE
    ALL TRANS RETINOIC ACID
    ACIDE RETINOIQUE (FRENCH)
    RETINOATE
    AGN 100335
    ALL-(E)-RETINOIC ACID
    TRETINOIN、ATRA
    TRETIN M
    EUDYNA
    TRANS-RETINOATE
    TRANS-RETINOIC ACID
    RENOVA®
    ATRA
    RETIONIC ACID
    TRETINOINA
    ALL-TRANS-VITAMIN A ACID
    ALL-TRANS-VITAMIN A1 ACID
    TRÉTINOÏNE
    ALL-TRANS-RETINOIC ACID
    (2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)NONA-2,4,6,8-TETRAENOIC ACID
    ALL-TRANS-RETINOIC ACID (ATRA)
    BETA-RETINOIC ACID
    RO 1-5488
    rxcui:10753
    pubchem.compound:444795
    chembl:CHEMBL38
    drugbank:00755
    chemidplus:302-79-4

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of acne
    Drug Class keratolytic agents
    Year of Approval 1988
    Drug Class antineoplastic agents
    (7 More Sources)

    Publications:

    Schrage et al., 2006, Macrophages and neurons are targets of retinoic acid signaling after spinal cord contusion injury., Eur. J. Neurosci.
    Redfern, 2004, Enhancing enhancers: new complexities in the retinoid regulation of gene expression., Biochem. J.
    Stafslien et al., 2007, Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay., Mol. Cell. Endocrinol.
    Hoegberg et al., 2005, Retinoid status and responsiveness to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking retinoid binding protein or retinoid receptor forms., Chem. Biol. Interact.
    Nagasawa et al., 2005, Effect of retinoic acid on murine preosteoblastic MC3T3-E1 cells., J. Nutr. Sci. Vitaminol.
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Reddy et al., 1992, Characterization and purification of human retinoic acid receptor-gamma 1 overexpressed in the baculovirus-insect cell system., Biochem. J.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kamei et al., 1993, Retinoic acid receptor gamma 2 gene expression is up-regulated by retinoic acid in 3T3-L1 preadipocytes., Biochem. J.
    Borger et al., 2000, Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-beta., Virology
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Fujishita et al., 2006, Upregulation of P2Y2 receptors by retinoids in normal human epidermal keratinocytes., Purinergic Signal.
    Day et al., 2006, Retinoic acid inhibits airway smooth muscle cell migration., Am. J. Respir. Cell Mol. Biol.
    Koda et al., 2007, Antiestrogenic activity of vitamin A in in vivo uterotrophic assay., Life Sci.
    He et al., 2007, Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway., J. Am. Soc. Nephrol.
    Wang et al., 2004, A novel retinoic acid-responsive element regulates retinoic acid-induced BLR1 expression., Mol. Cell. Biol.
    Mizuguchi et al., 2006, Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60., Biol. Pharm. Bull.
    Goto et al., 2011, Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment., Blood
    Tomita et al., 2013, Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia., Int. J. Hematol.
    Welch et al., 2011, Use of whole-genome sequencing to diagnose a cryptic fusion oncogene., JAMA
    Degos et al., 2001, All trans retinoic acid in acute promyelocytic leukemia., Oncogene
    Yoshida et al., 1996, Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway., Cancer Res.
    Hattori H et al., 2018, Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia., PLoS One
    Wang et al., 2007, Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha., Proc. Natl. Acad. Sci. U.S.A.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Harant et al., 1996, Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB., J. Biol. Chem.
    Ichikawa et al., 2015, Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene., Cancer Genet
    Balusu et al., 2011, Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1., Blood
    Burnett et al., 2010, The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA., Blood
    Butts et al., 2005, Transforming growth factor-beta1 signaling participates in the physiological and pathological regulation of mouse inner ear development by all-trans retinoic acid., Birth Defects Res. Part A Clin. Mol. Teratol.
    Xue et al., 2005, [Factors regulating expression of antiapoptosis gene survivin]., Zhongguo Shi Yan Xue Ye Xue Za Zhi
    Pratt et al., 2003, Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids., J. Cell. Biochem.
    Visani et al., 1996, All-trans retinoic acid and in vitro cytokine production by acute promyelocytic leukemia cells., Eur. J. Haematol.
    Zirn et al., 2005, All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo., Oncogene
    Youssef et al., 2004, Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers., Cancer Res.
    Nakashima K et al., 2015, Xanthones from the roots of Maclura cochinchinensis var. gerontogea and their retinoic acid receptor-α agonistic activity., Bioorg Med Chem Lett
    Kim H et al., 2008, Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative., Bioorg Med Chem
    Vollberg TM Sr et al., 1992, Retinoic acid receptors as regulators of human epidermal keratinocyte differentiation., Mol Endocrinol
    Pisani et al., 1997, In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts., Ann. Hematol.
    Reynolds et al., 2000, Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide., Med. Pediatr. Oncol.
    Sasaki et al., 2000, Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells., Brain Res. Mol. Brain Res.
    Lee et al., 1995, Induction of 73-kDa and 90-kDa heat shock protein expression in HL60 cells during differentiation., Tohoku J. Exp. Med.
    Mills et al., 2000, High FUS/TLS expression in acute myeloid leukaemia samples., Br. J. Haematol.
    Steidl U et al., 2005, Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera., Ann N Y Acad Sci
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Lucena-Araujo et al., 2014, Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study., Ann. Hematol.
    Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
  • TRETINOIN   RARRES1

    Interaction Score: 6.4

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    15897880 15059893


    Sources:
    TEND

  • TRETINOIN   PML

    Interaction Score: 6.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Fusion protein PML:RARA

    PMIDs:
    21613260 23670176 21505136 11704842 8674046 30289902


    Sources:
    CIViC PharmGKB FDA

  • TRETINOIN   FUS

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10691862


    Sources:
    NCI

  • TRETINOIN   BCOR

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type acute promyelocytic leukemia
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    25790901


    Sources:
    JAX-CKB

  • TRETINOIN   RXRG

    Interaction Score: 1.87

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name tretinoin microsponge,Retin-A
    Novel drug target Established target

    PMIDs:
    16420438 16456186 17161848 17182884 14993281


    Sources:
    TdgClinicalTrial TEND

  • TRETINOIN   RXRB

    Interaction Score: 1.66

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name tretinoin microsponge,Retin-A

    PMIDs:
    16420438 15379735 17184907 16109390 16392701


    Sources:
    TdgClinicalTrial TEND

  • TRETINOIN   RARG

    Interaction Score: 1.47

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Retinoic acid receptor agonist
    Direct Interaction yes
    Trial Name tretinoin microsponge,Retin-A

    PMIDs:
    10592235 1332684 11752352 8394693 10792999 17016423 17139284


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • TRETINOIN   P2RY2

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18404486


    Sources:
    NCI

  • TRETINOIN   RARA

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Retinoic acid receptor agonist
    Fusion protein PML:RARA

    PMIDs:
    25838141 18511283 1318502


    Sources:
    DTC ChemblInteractions PharmGKB FDA

  • TRETINOIN   MYCN

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11107126


    Sources:
    NCI

  • TRETINOIN   SMAD2

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15799023


    Sources:
    NCI

  • TRETINOIN   NPM1

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21719597 19965647


    Sources:
    CIViC

  • TRETINOIN   CDKN1B

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10837916


    Sources:
    NCI

  • TRETINOIN   RARB

    Interaction Score: 0.3

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Retinoic acid receptor agonist
    Direct Interaction yes

    PMIDs:
    15958702


    Sources:
    ChemblInteractions

  • TRETINOIN   HSPA8

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8578578


    Sources:
    NCI

  • TRETINOIN   IL10

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8982293


    Sources:
    NCI

  • TRETINOIN   BIRC5

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16403261 14587026


    Sources:
    NCI

  • TRETINOIN   FLT3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin
    Indication/Tumor Type acute promyelocytic leukemia
    Response Type sensitive

    PMIDs:
    24981688 19965647 27626069


    Sources:
    JAX-CKB CIViC

  • TRETINOIN   BCL2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9402847


    Sources:
    NCI

  • TRETINOIN   CXCL8

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8900181


    Sources:
    NCI

  • TRETINOIN   RXRA

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16946489


    Sources:
    DTC

  • TRETINOIN   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • TRETINOIN   KAT2A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRETINOIN   HIF1A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRETINOIN   USP1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRETINOIN   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TRETINOIN   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18048326


    Sources:
    DTC NCI

  • TRETINOIN   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRETINOIN   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: TRETINOIN

    • Version: 01-August-2011

    Alternate Names:
    TRETINOIN Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1988
    Drug Class keratolytic agents

    Publications:

  • TdgClinicalTrial: TRETINOIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of acne
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: ATRA

    • Version: 14-September-2017

    Alternate Names:
    C900 NCI drug code

    Drug Info:

    Publications:
    Pisani et al., 1997, In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts., Ann. Hematol.
    Lee et al., 1995, Induction of 73-kDa and 90-kDa heat shock protein expression in HL60 cells during differentiation., Tohoku J. Exp. Med.
    Wang et al., 2007, Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha., Proc. Natl. Acad. Sci. U.S.A.

  • DTC: TRETINOIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL38 ChEMBL Drug ID

    Drug Info:

    Publications:
    Nakashima K et al., 2015, Xanthones from the roots of Maclura cochinchinensis var. gerontogea and their retinoic acid receptor-α agonistic activity., Bioorg Med Chem Lett
    Kim H et al., 2008, Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative., Bioorg Med Chem
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • JAX-CKB: Tretinoin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
    Ichikawa et al., 2015, Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene., Cancer Genet

  • PharmGKB: tretinoin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

  • CIViC: TRETINOIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lucena-Araujo et al., 2014, Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study., Ann. Hematol.
    Burnett et al., 2010, The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA., Blood
    Balusu et al., 2011, Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1., Blood

  • TTD: Tretinoin

    • Version: 2020.06.01

    Alternate Names:
    D02DGU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL38

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL38

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Tretinoin

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21